Nasdaq – Talk Bio

Actionable Insights Powered by AI

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

1 month ago talkbio0Tagged Alzheimer 's disease, biotech, CNS disorder, IPO, MapLight Therapeutics, MPLT, Nasdaq, Phase 2 Clinical Trials, Psychotic Disorders, Public Offering, Schizophrenia

MapLight Therapeutics; IPO; Initial Public Offering; Nasdaq; MPLT; Schizophrenia; Alzheimer’s disease psychosis; CNS disorders; Phase 2 clinical trials; Biotech

LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months

3 months ago talkbio0Tagged IPO, IPOs, LBRX, Nasdaq, Phase III, Pounds, public entity, Schizophrenia

LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

3 months ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

6 months ago talkbio0Tagged Age-Related Diseases, biotech, biotech merger, Clinical Development, FutureTech II, Longevity, Nasdaq, Public Listing, SPAC

Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases

German cancer antibody biotech eyes SPAC as route to Nasdaq

8 months ago talkbio0Tagged Antibodies, German language, Nasdaq, SPAC, Veraxa

Veraxa, Antibodies, SPAC, German language, Nasdaq

Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing

10 months ago talkbio0Tagged biotech, Cystic Fibrosis, IPOs, Metabolic Diseases, Nasdaq, Obesity, Order Tubulidentata (organism)

Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment

Viracta Therapeutics Shuts Down Operations, Lays Off Entire Workforce

10 months ago talkbio0Tagged biotech closure, financial troubles, Nasdaq, oncology company, strategic alternatives, wind-down operations, workforce termination

biotech closure, oncology company, financial troubles, workforce termination, wind-down operations, Nasdaq delisting, strategic alternatives

Sionna Therapeutics Aims for $150 Million IPO to Advance Cystic Fibrosis Treatments

10 months ago talkbio0Tagged Clinical Trials, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, IPO, Nasdaq, NBD1, Proteins, Sionna, Stabilizer - function

Sionna Therapeutics, IPO, cystic fibrosis, CFTR protein, NBD1 stabilizers, biotech, Nasdaq, clinical trials

Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

10 months ago talkbio0Tagged biotech, Dosage Forms, IPOs, Kidney Diseases, Listings, Metsera, Nasdaq, Obesity

Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

1 year ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development